“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials
The revolution in cancer drug development has a caveat: Only a fraction of eligible patients take part in clinical trials. Historically, findings from studies estimate that the share of eligible ...
Data serves as the foundational pillar for all sales and marketing endeavors, and the absence of first- and third-party insights would leave practitioners formulating campaigns and devising strategies ...
New Study Finds Limited Value From Nearly One-Third of Clinical Trial Procedures and Associated Data, Highlighting Opportunity for More Patient-Centric Trial Design The study was designed to analyze ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback